EVT

Evotec SE trades at 4.70 euros in April 2026. Five years ago the same share traded above 45 euros. The company that once marketed itself as the integrated drug discovery and development partner of choice for global pharma has lost roughly 90 percent of its market value, and the operating results explain why. Revenue of 788 million euros in fiscal 2025 is essentially flat against 797 million euros in 2024 and 781 million euros in 2023. Four consecutive fiscal years of operating losses. Cumulative net losses since 2022 exceed 558 million euros. Shareholders' equity has been cut nearly in half from its 2021 peak.

This is a company that positioned itself as infrastructure for the biotech and pharma industry, yet finds itself unable to translate that positioning into operating leverage when its customers pull back. The central question for any structural reader of Evotec is not whether the platform has real scientific capabilities. It does. The question is whether a contract research organization with 4,766 employees, 554 million euros of property, plant and equipment, and a customer roster dependent on discretionary R&D budgets can ever be something other than a price taker in a cyclical service market.

The L17X observation that reframes Evotec: the company built a capital-intensive platform to support other people's drug pipelines, then discovered that the economics of drug discovery services do not reward capacity buildup. They reward flexibility. Evotec's 500 million euro property, plant and equipment base is not a moat. It is a fixed-cost millstone in a business where revenue visibility depends on the next pharma discovery budget cycle. The multi-modality strategy, the BRIDGES partnerships, the gene therapy manufacturing buildout at Just Evotec Biologics: each expansion was sold as strategic diversification. Each has delivered margin dilution rather than margin expansion. The incoming CEO Christian Wojczewski inherited a company with the cost structure of a platform operator and the revenue profile of a consultancy. That mismatch is the story.